1529 related articles for article (PubMed ID: 32519113)
1. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
[TBL] [Abstract][Full Text] [Related]
2. Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
Cowie MR; Lamy A; Levy P; Mealing S; Millier A; Mernagh P; Cristeau O; Bowrin K; Briere JB
Cardiovasc Res; 2020 Sep; 116(11):1918-1924. PubMed ID: 31807773
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
Zomer E; Si S; Hird TR; Liew D; Owen AJ; Tonkin A; Reid CM; Ademi Z
Eur J Prev Cardiol; 2019 May; 26(8):858-868. PubMed ID: 30526023
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands.
Spoorendonk JA; Briere JB; Bowrin K; Millier A; Coppens M; Tempelaar S; Verheggen B
J Med Econ; 2021; 24(1):1231-1239. PubMed ID: 34749569
[TBL] [Abstract][Full Text] [Related]
5. The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective.
Lamy A; Eikelboom J; Tong W; Yuan F; Bangdiwala SI; Bosch J; Connolly S; Lonn E; Dagenais GR; Branch KRH; Wang WJ; Bhatt DL; Probstfield J; Ertl G; Störk S; Steg PG; Aboyans V; Durand-Zaleski I; Ryden L; Yusuf S;
Am J Cardiovasc Drugs; 2024 Jan; 24(1):117-127. PubMed ID: 38153624
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of ankle-brachial index screening in patients with coronary artery disease to optimize medical management.
Minami HR; Itoga NK; George EL; Garcia-Toca M
J Vasc Surg; 2021 Dec; 74(6):2030-2039.e2. PubMed ID: 34175383
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy.
Ferrara P; Cortesi PA; Di Laura D; Maggioni AP; Mantovani LG
Clin Drug Investig; 2021 May; 41(5):459-468. PubMed ID: 33725323
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases.
Lee MC; Liao CT; Toh HS; Chou CC; Chang WT; Chen ZC; Wu WS; Yu T; Strong C
Cardiovasc Drugs Ther; 2021 Jun; 35(3):539-547. PubMed ID: 32910340
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial.
Lamy A; Eikelboom J; Tong W; Yuan F; Bangdiwala SI; Bosch J; Connolly S; Lonn E; Dagenais GR; Branch KRH; Wang WJ; Bhatt DL; Probstfield J; Ertl G; Störk S; Steg PG; Aboyans V; Durand-Zaleski I; Ryden L; Yusuf S
Eur Heart J Qual Care Clin Outcomes; 2023 Aug; 9(5):502-510. PubMed ID: 36001989
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of screening for peripheral artery disease in patients with coronary artery disease in China: A Markov model.
Xing Y; Qiu Y; Yang L; Yuan Z; Wang Y
Int J Cardiol; 2023 Jan; 371():420-426. PubMed ID: 36228765
[TBL] [Abstract][Full Text] [Related]
11. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Coppens M; Weitz JI; Eikelboom JWA
Circ Res; 2019 Feb; 124(3):416-425. PubMed ID: 30702997
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective.
Ademi Z; Zomer E; Tonkin A; Liew D
Int J Cardiol; 2018 Nov; 270():54-59. PubMed ID: 30220379
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials.
Bauersachs R; Wu O; Briere JB; Bowrin K; Borkowska K; Jakubowska A; Taieb V; Toumi M; Huelsebeck M
Cardiovasc Ther; 2020; 2020():3057168. PubMed ID: 32695228
[TBL] [Abstract][Full Text] [Related]
14. Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation.
Jacobs MS; de Jong LA; Postma MJ; Tieleman RG; van Hulst M
Eur J Health Econ; 2018 Sep; 19(7):957-965. PubMed ID: 29181817
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of antithrombotic agents for atrial fibrillation in older adults at risk for falls: a mathematical modelling study.
Wong EKC; Belza C; Naimark DMJ; Straus SE; Wijeysundera HC
CMAJ Open; 2020; 8(4):E706-E714. PubMed ID: 33158928
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pandor A; Pollard D; Chico T; Henderson R; Stevenson M
Pharmacoeconomics; 2016 May; 34(5):463-77. PubMed ID: 26689783
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China.
Dong SJ; Wu B; Zhai SD; Zhang YJ; Chu YB; Gupta P; Li YH
Clin Ther; 2020 Jan; 42(1):144-156.e1. PubMed ID: 31932080
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
Darmon A; Elbez Y; Bhatt DL; Abtan J; Mas JL; Cacoub P; Montalescot G; Billaut-Laden I; Ducrocq G; Steg PG
Ann Cardiol Angeiol (Paris); 2020 Oct; 69(4):158-166. PubMed ID: 32778388
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK.
Folkerts K; Broughton J; Sheikh U; Mckaig S
J Med Econ; 2019 Nov; 22(11):1179-1191. PubMed ID: 31433687
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function.
Salcedo J; Hay JW; Lam J
Int J Cardiol; 2019 May; 282():53-58. PubMed ID: 30518479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
